Search for: "BIOGEN IDEC U.S."
Results 41 - 60
of 69
Sort by Relevance
|
Sort by Date
15 Dec 2010, 7:36 am
Biogen IDEC et al. and Mayo Collaboratives Service, et al. v. [read post]
13 Dec 2010, 2:00 am
Biogen IDEC, Nos. 2006-1634 and 2006-1649. [read post]
13 Dec 2010, 2:00 am
Biogen IDEC, Nos. 2006-1634 and 2006-1649. [read post]
29 Sep 2010, 12:49 pm
Diehr, 450 U.S. 175 (1981). [read post]
15 Sep 2010, 8:39 am
Biogen Idec (method of determining an immunization schedule) and Association for Molecular Pathology v. [read post]
25 Aug 2010, 12:37 am
Biogen Idec, and Association for Molecular Pathology v. [read post]
17 Aug 2010, 9:52 pm
Biogen Idec, and Association for Molecular Pathology v. [read post]
5 Jul 2010, 11:19 am
Biogen Idec – to the Federal Circuit to reconsider the cases in light of the Bilski decision. [read post]
2 Jul 2010, 10:15 am
Biogen Idec, et al. [read post]
29 Jun 2010, 9:19 am
Biogen IDEC et al. (08-1509) The petition for a writ of certiorari is granted. [read post]
29 Jun 2010, 8:54 am
Biogen IDEC. [read post]
10 Jun 2010, 3:58 am
(Patent Docs) Avonex (Interferon) – US: Biogen launches submarine patent against competing providers of Interferon-Beta products: Biogen Idec MA Inc. v. [read post]
28 Mar 2010, 8:33 pm
Biogen Idec, Inc. et al. v. [read post]
27 Feb 2010, 3:23 pm
Biogen Idec presaged how arbitrary the Bilski test can be when applied to such drug/medical dosage calibration techniques. [read post]
28 Oct 2009, 9:29 am
The U.S. manufacturer, Boston’s Biogen Idec, said it was already considering a labeling change that would tell consumers that their risk of PML increases the longer they take Tysabri. [read post]
30 Sep 2009, 8:15 pm
Patent 7,588,755 (the '755 patent), issued on September 15, 2009, and owned by Biogen Idec. [read post]
24 May 2009, 10:58 pm
In the case IN RE GENENTECH, INC. and BIOGEN IDEC INC., the petitioners sought, and obtained, a writ of mandamus to move the patent case from ED Texas to ND California. [read post]
21 Apr 2009, 2:20 pm
We get some insightful additional information from a Dow Jones article, "Biogen Says Sixth MS Patient On Tysabri Gets Brain Infection": Tysabri - sold by the Cambridge, Mass., biotech [Biogen Idec Inc. [read post]
13 Apr 2009, 6:28 am
" The effects of Raptiva decrease the function of the immune system and increase susceptibility to infections (incidentally, PML is the same disease that has been linked to the multiple sclerosis drug Tysabri, sold by Biogen Idec and Elan). [read post]
8 Apr 2009, 11:47 am
There will be a phased voluntary withdrawal of psoriasis drug Raptiva from the U.S. market due to its link to a brain infection.Raptiva has recently been associated with an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and usually fatal disease of the central nervous system.Authorities in Europe, where Raptiva is sold by Merck KGaA (MRCG.DE), recommended in February that the drug be suspended in light of the PML risk.The European Commission is expected to follow… [read post]
